By Mill Chart
Last update: May 7, 2024
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a hidden gem unveiled by our stock screening tool, featuring a promising dividend outlook alongside solid fundamentals. NYSE:NVS demonstrates decent financial health and profitability while ensuring a sustainable dividend. Let's break it down further.
To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NYSE:NVS has achieved a 7 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:NVS has achieved a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVS has earned a 8 out of 10:
More Best Dividend stocks can be found in our Best Dividend screener.
Check the latest full fundamental report of NVS for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NOVARTIS AG-SPONSORED ADR
NYSE:NVS (5/17/2024, 7:17:02 PM)
After market: 102.57 0 (0%)102.57
-0.12 (-0.12%)
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
These three companies have track records that should please investors.
These three companies have track records that should please investors.
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital.
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?
The dividend is just one reason to buy these stocks.